Association of sFas and sFas ligand with progression of type 2 diabetes mellitus in Basrah province

• Published in: Medical Journal of Babylon Vol. 15; no. 2; pp. 135 - 138
• Main Authors: Hamid, Saja Majid, Shani, Wafa Sadun
• Format: Journal Article
• Language: English
• Published: Babylon, Iraq University of Babylon, College of Medicine 2018; Medknow Publications and Media Pvt. Ltd; Wolters Kluwer Medknow Publications
• Subjects: Analysis; Complications and side effects; Enzyme-linked immunosorbent assay; Insulin resistance; Ligands (Biochemistry); Prevention; Risk factors; sFas; sFas ligand; Type 2 diabetes; type 2 diabetes mellitus; Iraq
• ISSN: 1812-156X; 2312-6760
• DOI: 10.4103/MJBL.MJBL_25_18

Objective: This study aimed to assess the role of Fas/Fas ligand (FasL) system in the progression of type 2 diabetes mellitus (T2DM).
Materials and Methods: This study included 100 participants – 30 persons as a control group and 70 patients with T2DM (35 males and 35 females) and their ages were ranged from 40 to 70 years. The patients were distributed into two groups according to gender and duration of the disease: newly diagnosed group for short duration ≤5 years and chronic diagnosed group for long duration >5 years. Serum sFas and sFasL levels were measured by enzyme‑linked immunosorbent assay technique, and also, lipid and glucose profile were measured by COBAS analyzer.
Results: The results revealed a significant (P ≤ 0.05) decrement in the levels of FasL in T2DM than controls while the levels of Fas were increasing significantly (P ≤ 0.05) in T2DM than controls. Hemoglobin A1c (HbA1c) and fasting blood glucose were negatively correlated with FasL, while high‑density lipoprotein was positively correlated with it, and whereas HbA1c positively correlated with Fas, the gender and duration of disease did not show any correlation with the disease.
Conclusion: Our findings suggest that hyperglycemia causes increase in Fas levels which lead to dysfunction of pancreaticcell in T2DM.